Eisai Co., Ltd., a pharmaceutical company headquartered in Tokyo, Japan, develops and markets a wide array of medicinal products. Its offerings for neurological conditions include Aricept, prescribed for Alzheimer's disease and dementia with Lewy bodies; Methycobal, used to treat peripheral neuropathy; Fycompa, an antiepileptic drug that serves as an adjunctive therapy for specific partial-onset and primary generalized tonic-clonic seizures; Lyrica, for various pain management needs; and Dayvigo, an anti-insomnia medication for adults. In the oncology field, Eisai provides Lenvima, a molecularly targeted anticancer agent for thyroid cancer, renal cell carcinoma (when used in combination with everolimus), and hepatocellular carcinoma. Another key cancer treatment is Halaven, a microtubule dynamics inhibitor for breast cancer and liposarcoma. The company's portfolio also features Pariet, a proton-pump inhibitor effective in treating gastric and duodenal ulcers, reflux esophagitis, and for the eradication of Helicobacter pylori infections. Additionally, Eisai markets Humira, a fully human anti-TNF-alpha monoclonal antibody employed in managing autoimmune diseases such as rheumatoid arthritis. Beyond prescription medicines, Eisai provides consumer health products like Chocola BB Plus, a vitamin B2 preparation addressing rough skin and stomatitis, alongside various third-class over-the-counter (OTC) drugs, designated quasi-drugs, and functional foods. The company was established in 1941, initially operating as Nihon Eisai Co., Ltd., before adopting its current name, Eisai Co., Ltd., in 1955.
—
Eisai Co., Ltd., a pharmaceutical company headquartered in Tokyo, Japan, develops and markets a wide array of medicinal products. Its offerings for neurological conditions include Aricept, prescribed for Alzheimer's disease and dementia with Lewy bodies; Methycobal, used to treat peripheral neuropathy; Fycompa, an antiepileptic drug that serves as an adjunctive therapy for specific partial-onset and primary generalized tonic-clonic seizures; Lyrica, for various pain management needs; and Dayvigo, an anti-insomnia medication for adults. In the oncology field, Eisai provides Lenvima, a molecularly targeted anticancer agent for thyroid cancer, renal cell carcinoma (when used in combination with everolimus), and hepatocellular carcinoma. Another key cancer treatment is Halaven, a microtubule dynamics inhibitor for breast cancer and liposarcoma. The company's portfolio also features Pariet, a proton-pump inhibitor effective in treating gastric and duodenal ulcers, reflux esophagitis, and for the eradication of Helicobacter pylori infections. Additionally, Eisai markets Humira, a fully human anti-TNF-alpha monoclonal antibody employed in managing autoimmune diseases such as rheumatoid arthritis. Beyond prescription medicines, Eisai provides consumer health products like Chocola BB Plus, a vitamin B2 preparation addressing rough skin and stomatitis, alongside various third-class over-the-counter (OTC) drugs, designated quasi-drugs, and functional foods. The company was established in 1941, initially operating as Nihon Eisai Co., Ltd., before adopting its current name, Eisai Co., Ltd., in 1955.
—
Daily adjusted close
Eisai Co., Ltd., a pharmaceutical company headquartered in Tokyo, Japan, develops and markets a wide array of medicinal products. Its offerings for neurological conditions include Aricept, prescribed for Alzheimer's disease and dementia with Lewy bodies; Methycobal, used to treat peripheral neuropathy; Fycompa, an antiepileptic drug that serves as an adjunctive therapy for specific partial-onset and primary generalized tonic-clonic seizures; Lyrica, for various pain management needs; and Dayvigo, an anti-insomnia medication for adults. In the oncology field, Eisai provides Lenvima, a molecularly targeted anticancer agent for thyroid cancer, renal cell carcinoma (when used in combination with everolimus), and hepatocellular carcinoma. Another key cancer treatment is Halaven, a microtubule dynamics inhibitor for breast cancer and liposarcoma. The company's portfolio also features Pariet, a proton-pump inhibitor effective in treating gastric and duodenal ulcers, reflux esophagitis, and for the eradication of Helicobacter pylori infections. Additionally, Eisai markets Humira, a fully human anti-TNF-alpha monoclonal antibody employed in managing autoimmune diseases such as rheumatoid arthritis. Beyond prescription medicines, Eisai provides consumer health products like Chocola BB Plus, a vitamin B2 preparation addressing rough skin and stomatitis, alongside various third-class over-the-counter (OTC) drugs, designated quasi-drugs, and functional foods. The company was established in 1941, initially operating as Nihon Eisai Co., Ltd., before adopting its current name, Eisai Co., Ltd., in 1955.